脂肪酸样 Pt(IV)前药通过利用 CD36 克服卵巢癌中的顺铂耐药性。
Fatty acid-like Pt(IV) prodrugs overcome cisplatin resistance in ovarian cancer by harnessing CD36.
机构信息
Department of Chemistry and Biochemistry, Kent State University, Kent, OH 44242, USA.
出版信息
Chem Commun (Camb). 2020 Sep 15;56(73):10706-10709. doi: 10.1039/d0cc02174a.
PMID:32789350
Abstract
Resistance to the platinum-based chemotherapy drug, cisplatin, is a significant setback in ovarian cancer. We engineered fatty acid-like Pt(iv) prodrugs that harness the fatty acid transporter CD36 to facilitate their entry to ovarian cancer cells. We show that these novel constructs effectively kill cisplatin-resistant ovarian cancer cells.
摘要
对基于铂的化疗药物顺铂的耐药性是卵巢癌的一个重大挫折。我们设计了脂肪酸样的 Pt(iv)前药，利用脂肪酸转运蛋白 CD36 促进它们进入卵巢癌细胞。我们表明，这些新型构建体有效地杀死了顺铂耐药的卵巢癌细胞。
Zotero 插件